Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging

scientific article published on 07 June 2018

Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00259-018-4059-3
P932PMC publication ID6286257
P698PubMed publication ID29882161

P50authorYonglin PuQ88757229
P2093author name stringHaiyan Liu
James X Zhang
Daniel Appelbaum
Jianfeng Meng
Bill C Penney
P2860cites workPrognostic Significance of Volume-based Metabolic Parameters by (18)F-FDG PET/CT in Gallbladder CarcinomaQ33704511
Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung CancerQ33704656
Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancerQ34977651
Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.Q35474006
Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET ImagesQ35637414
A new PET/CT volumetric prognostic index for non-small cell lung cancerQ35688617
Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer.Q35731341
Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake timesQ36304366
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.Q36495076
What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantomQ37424511
Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancerQ38014317
Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesQ38104633
Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic valueQ38136865
Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysisQ38246442
Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database surveyQ38447643
Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinibQ38895657
Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancerQ38925887
Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancerQ39127172
Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resectionQ43632922
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.Q50909685
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.Q51005942
Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.Q51602164
Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary?Q53014495
FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.Q53089675
Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.Q53140054
Metabolic tumor burden predicts for disease progression and death in lung cancer.Q53463840
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerQ57272532
Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancerQ82811825
Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancerQ83620716
P433issue12
P1104number of pages14
P304page(s)2079-2092
P577publication date2018-06-07
P1433published inEuropean Journal of Nuclear Medicine and Molecular ImagingQ15708890
P1476titleDeveloping and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging
P478volume45

Reverse relations

Q92541829Development and External Validation of a Nomogram for Predicting Survival in Patients With Stage IA Non-small Cell Lung Cancer ≤2 cm Undergoing Sublobectomycites workP2860

Search more.